Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.05)
# 2,936
Out of 4,983 analysts
112
Total ratings
38.38%
Success rate
-5.32%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLNN Clene | Maintains: Buy | $83 → $48 | $6.33 | +658.29% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $5.10 | +194.12% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $8.11 | +232.92% | 6 | Jul 29, 2025 | |
| ATAI Atai Life Sciences | Maintains: Buy | $12 → $11 | $4.65 | +136.56% | 3 | Jul 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $73 → $70 | $6.04 | +1,058.94% | 8 | Jul 8, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $2.37 | +617.30% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $140.90 | +13.56% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $143.68 | +53.12% | 21 | May 2, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $7.26 | +244.35% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $4.25 | +182.35% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $2.99 | +2,575.59% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $12.63 | +121.69% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $9.71 | +44.18% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $23.16 | -13.64% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $23.96 | +37.73% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $13.49 | +1,011.93% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $18.68 | - | 2 | Jan 31, 2017 |
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $6.33
Upside: +658.29%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $5.10
Upside: +194.12%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $8.11
Upside: +232.92%
Atai Life Sciences
Jul 28, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $4.65
Upside: +136.56%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $6.04
Upside: +1,058.94%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $2.37
Upside: +617.30%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $140.90
Upside: +13.56%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $143.68
Upside: +53.12%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $7.26
Upside: +244.35%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.25
Upside: +182.35%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.99
Upside: +2,575.59%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $12.63
Upside: +121.69%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $9.71
Upside: +44.18%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $23.16
Upside: -13.64%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $23.96
Upside: +37.73%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $13.49
Upside: +1,011.93%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $18.68
Upside: -